|
|
Volumn 55, Issue 7, 2015, Pages 725-727
|
|
FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDEPRESSANT AGENT;
CODEINE;
DRUG METABOLIZING ENZYME;
ACCREDITATION;
CLINICAL LABORATORY;
CLINICAL RESEARCH;
CURRENT PROCEDURAL TERMINOLOGY;
DEVICE APPROVAL;
DRUG APPROVAL;
DRUG COST;
DRUG THERAPY;
ECONOMIC EVALUATION;
FOOD AND DRUG ADMINISTRATION;
FUNDING;
GENETIC VARIABILITY;
GENOTYPING TECHNIQUE;
HUMAN;
LABORATORY TEST;
LAW;
MEDICAID;
MEDICAL DEVICE REGULATION;
MEDICAL PRACTICE;
MEDICAL TECHNOLOGY;
MEDICARE;
NOTE;
PHARMACODYNAMICS;
PHARMACOGENETICS;
PHARMACOGENOMICS;
PHARMACOKINETICS;
PRACTICE GUIDELINE;
REIMBURSEMENT;
CLINICAL LABORATORY SERVICE;
ECONOMICS;
LEGISLATION AND JURISPRUDENCE;
PROCEDURES;
RISK;
STANDARDS;
UNITED STATES;
CLINICAL LABORATORY SERVICES;
CLINICAL LABORATORY TECHNIQUES;
HUMANS;
PHARMACOGENETICS;
RISK;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84930642392
PISSN: 00912700
EISSN: 15524604
Source Type: Journal
DOI: 10.1002/jcph.492 Document Type: Note |
|
Times cited : (6)
|
|
References (4)
|
